vimarsana.com

Latest Breaking News On - Novartis zolgensma - Page 1 : vimarsana.com

Where Cell Therapies Are Going Next, and How Insurers Are Getting Ready

Multiple efforts are underway to improve cell therapies for cancer. During the MedCity News INVEST conference in Chicago, a panel discussed the future of cell therapies and what the industry doing to manage the financial risks of these new treatments.

Swiss start-up sets out to lower cost of gene therapy

Swiss start-up NewBiologix is one of a growing number of companies setting up shop in Switzerland to meet the demands of gene and cell therapy makers.

CRISPR cures for sickle cell disease raise equity concerns

China 2022 National Reimbursement Drug List Drug Pricing

China National Healthcare Security Administration NHSA published 2022 National Reimbursement Drug List 2022 NRDL, implementing comparable level of pricing discounts to those seen in 2021. Out of 147 drugs negotiated, 121 were successfully added to 2022 NRDL, including 91 exclusive.

World s most expensive drug approved at $5m a dose

CSL Behring’s haemophilia B gene therapy, a one-off infusion that frees patients from regular treatments, costs $US3.5 million ($5.2 million) a dose, making it the most expensive medicine in the world.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.